Ferring Pharmaceuticals knows that birthing babies is hard work. The company develops and sells a variety of fertility products for the US market, including hormone treatments Bravelle, Menopur, and Endometrin. The company also develops and manufactures products to diagnose and treat ailments in the areas of urology, endocrinology, inflammation, oncology, and gastroenterology, including Euflexxa for osteoarthritis of the knee, Prosed for lower urinary tract infections, prostate cancer treatment Firmagon, and Lysteda for heavy menstrual periods. Ferring Pharmaceuticals is owned by Swiss drugmaker Ferring Group, which was founded in 1951 and expanded into the US in the early 1980s.
The global Ferring organization has manufacturing plants, R&D centers, and marketing offices in some 50 countries. In the US, Ferring Pharmaceuticals primarily provides sales and marketing services from its office in New Jersey for products manufactured at global Ferring Group locations.
Ferring Pharmaceuticals also operates the Ferring Research Institute in California. The research and development center is focused on the development of peptide (amino acid compound) therapeutics, as well as drug delivery technologies. Ferring opened a new research center, called the Ferring International PharmaScience Center US, at its main New Jersey location in 2008 to extend its R&D efforts.
To expand beyond infertility and into general gynecology drugs, in 2010 the company acquired the rights to Lysteda, a treatment for heavy menstrual bleeding. The non-hormonal drug was developed by Xanodyne Pharmaceuticals and received FDA approval in 2009. In 2011 the company expanded further in the field of reproductive health by purchasing obstetrics-focused biopharmaceutical firm Cytokine PharmaSciences Inc. (CPSI) and its Controlled Therapeutics (Scotland) Ltd. (CTS) subsidiary. The CPSI acquisition included the manufacturing assets for dinoprostone, a cervical ripening treatment for labor induction, which Ferring markets as PROPESS® outside the US and Forest Laboratories markets in the US and Canada as CERVIDIL®. CTS has in its pipeline a misoprostol vaginal insert for cervical ripening that is expected to be filed for FDA approval in 2012 and marketed as MISODEL® in the US and Canada and as MISOPESS® elsewhere.
Ferring Pharmaceuticals also adds to its product offerings by forming distribution partnerships with other drug manufacturers; for instance, it formed a partnership with Xanodyne in 2010 to market pain medicine Zipsor in the US. – less